Trial
NCT07524257
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
ImmunityBio, Inc.
Collaborators
—
Condition
NSCLC (Advanced Non-small Cell Lung Cancer)
Intervention
Drug: Nogapendekin alfa inbakicept (NAI)
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-22